Checklist for Prescribers:
Initiation of TRUVADA® for Pre-exposure Prophylaxis (PrEP)

Instructions: Complete checklist at each visit and file in individual’s medical record.

I have completed the following prior to prescribing TRUVADA for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking TRUVADA for a PrEP indication:

☐ Completed high risk evaluation of uninfected individual

☐ Confirmed a negative HIV-1 test immediately prior to initiating TRUVADA for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: TRUVADA for a PrEP indication is contraindicated in individuals with unknown HIV-1 status or who are HIV-1 positive)

☐ Discussed known safety risks with use of TRUVADA for a PrEP indication

☐ Counseled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking TRUVADA for PrEP to confirm HIV-1 status

☐ Discussed the importance of discontinuing TRUVADA for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants

☐ Counseled on the importance of adherence to daily dosing schedule

☐ Counseled that TRUVADA for a PrEP indication should be used only as part of a comprehensive prevention strategy

☐ Educated on practicing safer sex consistently and using condoms correctly

☐ Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)

☐ Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission

☐ Performed HBV screening test. Offered HBV vaccination as appropriate

☐ Confirmed creatinine clearance (CrCl) $\geq$60 mL/min. If a decrease in CrCl is observed in uninfected individuals while using TRUVADA for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use

☐ Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or hepatitis B medications

☐ Provided education on where information about PrEP can be accessed

☐ Discussed potential adverse events and side effects

☐ Reviewed the TRUVADA Medication Guide with the uninfected individual at high risk

☐ Evaluated risk/benefit for women who may be pregnant or may want to become pregnant